Publications by authors named "Deborah Baik"
Article Synopsis
- Inflammatory bowel disease (IBD) guidelines advocate for using TNF inhibitors like infliximab for those who don’t respond to standard treatments, and vedolizumab as an alternative when needed.
- A study used a Markov model to analyze the cost-effectiveness of different biologic treatments over a 10-year period for patients with ulcerative colitis (UC) and Crohn's disease (CD) in the UK and France.
- Results showed that starting treatment with infliximab was both more cost-effective and effective than starting with vedolizumab, supporting existing health recommendations in the UK.
Article Synopsis
- The study investigates the common practice of using anticholinergics and acetylcholinesterase inhibitors (ACHEIs) simultaneously in elderly Korean patients with Parkinson's disease (PD) and dementia, which can decrease treatment effectiveness due to their opposing effects.
- Among 8,845 PD patients with dementia, 9.58% were found to be using both drug types together, with many being prescribed by the same doctor, suggesting potential issues with communication about their treatment plans.
- The findings indicate a higher likelihood of concurrent use among patients treated at clinics and hospitals rather than tertiary care centers, and those in non-capital city areas face a 22% increased risk, highlighting the need for better management strategies in prescribing these medications.
Background: Patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) treated with pralatrexate have previously shown superior overall survival (OS) compared to those who underwent conventional chemotherapy (CC, 15.4 vs. 4.
View Article and Find Full Text PDFAims: Haemophilia A patients with factor VIII inhibitors (HAPI) experience frequent spontaneous bleeding, approximately once a week, and require expensive bypassing agent (BPA) treatments to control bleeding over their lifetime. According to the HAVEN 1 trial, weekly emicizumab (Hemlibra®) prophylaxis injection reduces annualized bleeding rates (ABR) by 87% compared with BPA on-demand treatment (BPA-OD) administered at the time of bleeding. Our study aimed to assess the cost-effectiveness of emicizumab prophylaxis in HAPI in Korea.
View Article and Find Full Text PDF